PHARMACIE BASTILLE : revenue, balance sheet and financial ratios

In 2024, PHARMACIE BASTILLE achieves revenue of 4.7 M€. Over the period 2015-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +13.9%. Vs 2023: +7%. After deducting consumption (3.2 M€), gross margin stands at 1.4 M€, i.e. a rate of 31%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 31 k€, representing 0.7% of revenue. Positive scissor effect: EBITDA margin improves by +3.5 pts, sign of improved operational efficiency. The operating margin remains fragile, requiring cost vigilance. Net income is negative at -229 € (-0.0% of revenue), which will impact equity.

The debt ratio (= Financial debt / Equity x 100) stands at 58%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 42%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 17.6 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 0.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

The liquidity ratio (= Current assets / Current liabilities) stands at 234.01. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 14.3x. Operating income very largely covers interest expenses: high safety margin.

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 15 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 37 days. Favorable situation: supplier credit is longer than customer credit by 22 days. Inventory turnover is 82 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 84 days of revenue, i.e. 1.1 M€ to permanently finance. Over 2015-2024, WCR increased by +401%, requiring additional financing.

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE BASTILLE is estimated at 1 300 393 € (range 1 057 660€ - 1 690 635€). With an EBITDA of 30 618€, the sector multiple of 9.2x is applied. The price/revenue ratio is 0.64x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.